showed that allogeneic CAR-iNKT cells exerted anti-tumor activity through cross-priming of CD8+ T cells, and were more effective at tumor control than conventional CAR T cells in the presence of host lymphocytes (26). The gene discussed is CD8A; the disease is neoplasm.